Arena Pharmaceuticals recently announced that enrollment in its ralinepag phase 2 trial has been finalized.
Ralinepag is a selective IP receptor agonist designed to target the prostacyclin pathway, in order to treat pulmonary arterial hypertension (PAH).
It is administered orally. Enrollment for the study includes approximately 60 patients at sites across the world.
"This marks an important step in the development of ralinepag and is evidence of our strategic focus on our pipeline," Arena President and CEO Amit Munshi said. "We believe ralinepag has the potential to achieve a best-in-class profile for patients suffering from PAH and we look forward to seeing the results mid-year to confirm our hypothesis."
The phase 2 trial is scheduled to last a period of 22 weeks and will be randomized, double-blind and placebo-controlled. It will assess ralinepag’s effectiveness when it comes to the reduction of pulmonary vascular resistance and the improvement of exercise capacity, tolerability and safety.
